Betamethasone (Pharma-q Betamethasone)
Betamethasone
Pharma-q Holdings (Pty) Ltd
Registration
- Applicant
- Pharma-q Holdings (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharma-q betamethasone injection 4 mg/1 ML EACH 1,0 ml SOLUTION CONTAINS BETAMETHASONE SODIUM PHOSPHATE EQUIVALENT TO BETAMETHASONE 4,0 mg | 4 mg/1 mlInjection | 32033832/21.5.1/0338 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Betamethasone
Consolidated Schedules 06 July 2026, line 5481
S3: Calcipotriol
Consolidated Schedules 06 July 2026, line 3258
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(8S,9R,10S,11S,13S,14S,16S,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Drag to rotate. Structure from PubChem CID 9782.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.